Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: Actions and outcomes

Multiple Sclerosis

Volumn 10, Issue 3, 2004, Pages 298-301

  Tremlett, Helen L ^a   Oger, Joel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adverse drug reaction; Aminotransferase; Interferon beta; Liver; Multiple sclerosis; Pharmacovigilance

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANADA; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HEPATITIS, TOXIC; HUMANS; INTERFERON-BETA; LIVER; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; TRANSAMINASES;

EID: 3042599922     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1007oa     Document Type: Article

References (8)

1. Stricker B ed. Drug-induced hepatic injury, second edition. Amsterdam: Elsevier, 1992: 402-405.
2. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E et al. Liver and thyroid function and autoimmunity during interferon-beta1b treatment for Multiple Sclerosis. Neurology 2001; 57: 1363-70.
3. Tremlett HL, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im). Neurology 2004 62: 628-31.
4. Anonymous. National Cancer Institute. Cancer Therapy Evaluation Program. Common toxicity criteria, Version 2. DCTD, NCI, NIH, DHHS. Revised March 1998, published April 1999 (http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf; accessed 19 November 2002).
5. Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW et al. Fulminant liver failure during interferon beta treatment of Multiple Sclerosis. Neurology 2001; 56: 1416.
6. Benichou C, The Council for International Organisations of Medical Sciences (CIOMS). Criteria of drug-induced liver disorders. J Hepatol 1990; 11: 272-76.
7. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liver Dis 2002; 22: 145-55.
8. Renton KW. Alterations of drug biotransformation and elimination during infection and inflammation. Pharmacol Therapeutics 2001; 92: 147-63.